Tenderwize
Back to tender search

Open-House Biologics Discount Contracts 2025-02 - Rituximab (Subcutaneous Injection Form)

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 193 days left·Open·Supplies
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-02 - Rituximab (Darreichungsform zur subkutanen Injektion)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

25 / 100

Risk factors

If the patent for Rituximab subcutaneous expires before the contract end (28.02.2027), the contract terminates automati...

No estimated volume or value is provided; actual sales may be low if many participants join.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Conclusion of pharmaceutical discount contracts for Rituximab (subcutaneous injection form) with all eligible pharmaceutical entrepreneurs under an open-house procedure.
Show full summary

Open-house procedure for discount contracts (Rabattverträge) for the active substance Rituximab (subcutaneous injection form) under §130a Abs. 8 SGB V. The procedure is open to all eligible pharmaceutical entrepreneurs who can offer or intend to offer the product. Uniform conditions apply, no exclusivity, and contracts can be concluded at any time during the 24-month period from March 2025 to February 2027.

Risks

If the patent for Rituximab subcutaneous expires before the contract end (28.02.2027), the contract terminates automati...

No estimated volume or value is provided; actual sales may be low if many participants join.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in §4 Abs. 18 AMG.
  • Must have a valid marketing authorization for the product or be entitled to market it in own name.

Eligibility

  • Must declare eligibility and reliability via a self-declaration (Anlage 4 zum Vertrag).

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Contracts 2025-02 - Rituximab (Subcutaneous Injection Form)

Conclusion of discount contracts for Rituximab subcutaneous injection form with any eligible pharmaceutical entrepreneur.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Feb 2025 - Feb 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 27, 2027

Procurement Details

Publication date
23 Jan 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
50192-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)

Sep 15
1 SME lot

Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów

Sep 17

France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord

Sep 14
6 SME lots

Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)

Aug 27
3 framework lots3 SME lots

Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ

Sep 18

Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).

Sep 24